Showing 1331-1340 of 3001 results for "".
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- In Utero Exposure to Ocrevus Not Associated with Elevated Adverse Outcomes in Pregnancyhttps://practicalneurology.com/news/in-utero-exposure-to-ocrevus-not-associated-with-elevated-adverse-outcomes-in-pregnancy/2470314/In a study of the largest available dataset for pregnancy outcomes for an anti-CD20 monoclonal antibody therapy, in utero exposure to Ocrevus (ocrelizumab; Genentech, South San Francisco, CA), a medication used to treat multiple sclerosis (MS), was not associated with an elevated risk of preterm
- Vaccinations Not Associated with Multiple Sclerosis Flare-ups According to New Studyhttps://practicalneurology.com/news/vaccinations-not-associated-with-multiple-sclerosis-flare-ups-according-to-new-study/2470300/According to results from a nationwide French study published in JAMA Neurology, there was no association between vaccinations and incidence of severe multiple sclerosis (MS) flare-ups requiring hospitalization. The findings were consistent regardless of age range, whether the participan
- Researchers Confirm 4 Genes Associated with Increased Risk of Developing PMLhttps://practicalneurology.com/news/researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml-researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml/2470291/Researchers have identified 4 genes associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML) in patients taking 99 different PML-linked drugs for a variety of conditions, including multiple sclerosis (MS), blood cancers, and rheumatoid arthritis. This study
- With High Costs and Similar Benefits, Use of New Neurologic Drugs Is Lowhttps://practicalneurology.com/news/with-high-costs-and-similar-benefits-use-of-new-neurologic-drugs-is-low/2470073/A study published in Neurology showed that a number of new neurologic medications for diseases such as multiple sclerosis (MS), Parkinson disease (PD), and migraine have received Food and Drug Administration (FDA) approval, but only a small percentage of patients are being treated with t
- Climate Change May Worsen Neurologic Disease Symptomshttps://practicalneurology.com/news/climate-change-may-worsen-neurologic-disease-symptoms/2470067/According to a review of published studies on climate change, people with neurologic diseases such as migraine, dementia, Multiple Sclerosis (MS), and Parkinson disease (PD) may experience worsening symptoms and stroke may be more prevalent due to climate change. The review
- Virtual Reality Technology is Feasible for Treating Upper Limb Dysfunction in Multiple Sclerosishttps://practicalneurology.com/news/virtual-reality-technology-is-feasible-for-treating-upper-limb-dysfunction-in-multiple-sclerosis/2470056/Results from a new study published in JMIR Serious Games shows that virtual reality technology is safe and improves functionality for upper limb dysfunction in individuals with Multiple Sclerosis (MS). The software is safe, reliable, and engaging. "The study proves that virtual rea
- Long-Term Efficacy and Safety of Evobrutinib for Multiple Sclerosis Results Over 144-Week Clinical Studieshttps://practicalneurology.com/news/long-term-efficacy-and-safety-of-evobrutinib-for-multiple-sclerosis-results-over-144-week-clinical-studies/2469930/In the open-label extension of a phase 2 clinical trial (NCT02975349), participants with multiple sclerosis (MS) treated with the investigational Bruton tyrosine kinase inhibitor evobrutinib (EMD Serono, Rockland, MA) continued to have a low annualized relapse rate (ARR). For individuals treated
- Translingual Neuromodulator to Assist Ambulation in Multiple Sclerosis Now Available in UShttps://practicalneurology.com/news/translingual-neuromodulator-to-assist-ambulation-in-multiple-sclerosis-now-available-in-us/2469898/Helius Medical Technologies (Newtown, PA) has announced that their translingual neuromodulation (portable neuromodulation stimulator [PONS]) device, shown to assist walking in people with multiple sclerosis (MS), is now available in the US. The PONS device is a portable, nonimplant neuromod
- Evobrutinib Reduces Relapsing Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/evobrutinib-reduces-relapsing-multiple-sclerosis-disease-activity/2469723/Post-hoc analysis of data from a phase 2 study (NCT02975349) of evobrutinib (M2951; EMD Serono, Rockland, MA) reduced the volume of slowly expanding MRI lesions in participants with relapsing multiple sclerosis (MS). Slowly expanding l